Contraception

Clinical testing of transdermal contraceptive spray begins

Published in Women's Health Weekly, December 9th, 2004

The Population Council and Acrux Limited (ASX: ACR), an Australian pharmaceutical company that specializes in administering drugs through the skin, announced on November 15, 2004, the start of the clinical study of a new type of contraceptive for women: the Nestorone Metered Dose Transdermal System (MDTS).

"We hope the development of Nestorone MDTS as a transdermal contraceptive will offer women and couples a new option in meeting their family planning needs with confidence and ease. This first study will provide us with the information necessary before we begin the contraceptive efficacy trial," said Sandra Arnold, the Population Council's vice president of corporate...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-12-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry